Download PDF
CC BY-NC-ND 4.0 · Geburtshilfe Frauenheilkd 2024; 84(05): 431-442
DOI: 10.1055/a-2263-5152
GebFra Science
Review/Übersicht

ABC7-Konsens – diskutiert vor dem Hintergrund deutscher Empfehlungen

Article in several languages: English | deutsch
Michael Untch
1   Klinik für Gynäkologie und Geburtshilfe, interdisziplinäres Brustzentrum, HELIOS Klinikum Berlin Buch, Berlin, Germany
,
Nina Ditsch
2   Klinik für Frauenheilkunde und Geburtshilfe, Brustzentrum, Universitätsklinikum Augsburg, Augsburg, Germany
,
Peter A. Fasching
3   Frauenklinik des Universitätsklinikums Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
,
Steffi Busch
4   Onkologische Schwerpunktpraxis, Dr. Busch MVZ GmbH, Mühlhausen,Germany
,
Johannes Ettl
5   Klinik für Gynäkologie und Geburtshilfe, Klinik für Hämatologie, Onkologie und Palliativmedizin, Klinikverbund Allgäu gGmbH, Klinikum Kempten, Kempten, Germany
,
Renate Haidinger
6   Brustkrebs Deutschland e. V., Hohenbrunn, Germany; patient advocate, board member ABC Global Alliance
,
Nadia Harbeck
7   Brustzentrum, Frauenklinik und Comprehensive Cancer Center (CCC), LMU Klinikum München, München, Germany; ABC7 panel member
,
Christian Jackisch
8   Klinik für Gynäkologie und Frauenheilkunde, Sana Klinikum Offenbach, Offenbach, Germany
,
Diana Lüftner
9   Immanuel Klinik Märkische Schweiz, Buckow & Immanuel Klinik Rüdersdorf, Medizinische Hochschule Brandenburg, Rüdersdorf bei Berlin, Germany
,
Lothar Müller
10   Onkologie UnterEms, Studienzentrum UnterEms, Leer, Germany
,
Eugen Ruckhäberle
11   Universitätsfrauenklinik, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany
,
Eva Schumacher-Wulf
12   Mamma Mia! Brustkrebsmagazin, Köln, Germany; patient advocate, co-chair, ABC7 panel member
,
Christoph Thomssen
13   Klinik und Poliklinik für Gynäkologie, Martin-Luther-Universität Halle-Wittenberg, Halle (Saale), Germany
,
Rachel Wuerstlein
14   Brustzentrum, Frauenklinik und Comprehensive Cancer Center (CCC), LMU Klinikum München, München, Germany
,
Volkmar Müller
15   Klinik und Poliklinik für Gynäkologie, Universitätsfrauenklinik und Brustzentrum Hamburg-Eppendorf, Hamburg Germany; ABC7 panel member
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Zusammenfassung

Ziel der „Internationalen Konsenskonferenz zum fortgeschrittenen Mammakarzinom“ (International Consensus Conference for Advanced Breast Cancer [ABC]) ist es, die Behandlung der Patientinnen mit fortgeschrittenem bzw. metastasiertem Mammakarzinom auf evidenzbasierter Grundlage weltweit zu standardisieren und sicherzustellen, dass in allen Ländern eine adäquate Behandlung mit Zugang zu den aktuellen Therapieempfehlungen und -standards ermöglicht wird. Die mittlerweile 7. „Internationale Konsenskonferenz zum fortgeschrittenen Mammakarzinom“ (ABC7) fand vom 9.–12. November 2023 in Lissabon/Portugal statt. ABC7 fokussierte neben der metastasierten Erkrankung auch auf das lokal fortgeschrittene und das inflammatorische Mammakarzinom. Spezielle Themen waren unter anderem die Behandlung oligometastasierter Patientinnen, die leptomeningeale Erkrankung, die Behandlung von Hirnmetastasen sowie von schwangeren Patientinnen mit fortgeschrittenem Mammakarzinom. Wie schon in den vergangenen Jahren nahmen auch Patientenvertreterinnen aus der ganzen Welt an der Konferenz teil und waren an der Konsensfindung beteiligt.

Schlüsselwörter

ABC und Schwangerschaft - Systemtherapie - ADCs - Oligometastasierung - Hirnmetastasen - leptomeningeale Erkrankung


Publication History

Received: 05 February 2024

Accepted: 11 March 2024

Article published online:
29 May 2024

© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References/Literatur

  • 1 Thill M, Kolberg-Liedtke C, Albert U-S. et al. AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2023. Breast Care (Basel) 2023; 18: 306-315
    CrossrefPubMedSearch in Google Scholar
  • 2 Dykewicz CA. Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients. Clin Infect Dis 2001; 33: 139-144
    CrossrefPubMedSearch in Google Scholar
  • 3 Kowalski ES, Feigenberg SJ, Cohen J. et al. Optimal Target Delineation and Treatment Techniques in the Era of Conformal Photon and Proton Breast and Regional Nodal Irradiation. Pract Radiat Oncol 2020; 10: 174-182
    CrossrefPubMedSearch in Google Scholar
  • 4 Davidson T, Ben-David M, Galper S. et al. Use of 18F-FDG PET-CT imaging to determine internal mammary lymph node location for radiation therapy treatment planning in breast cancer patients. Pract Radiat Oncol 2017; 7: 373-381
    CrossrefPubMedSearch in Google Scholar
  • 5 Jacene HA, DiPiro PJ, Bellon J. et al. Discrepancy between FDG-PET/CT and contrast-enhanced CT in the staging of patients with inflammatory breast cancer: implications for treatment planning. Breast Cancer Res Treat 2020; 181: 383-390
    CrossrefPubMedSearch in Google Scholar
  • 6 Schmid P, Cortes J, Dent R. et al. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. N Engl J Med 2022; 386: 556-567
    CrossrefPubMedSearch in Google Scholar
  • 7 Cortes J, Rugo HS, Cescon DW. et al. Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer. N Engl J Med 2022; 387: 217-226
    CrossrefPubMedSearch in Google Scholar
  • 8 Maio M, Shapira-Frommer R, Yap TA. et al. Abstract CT178: Olaparib plus pembrolizumab in patients with previously treated advanced solid tumors with homologous recombination repair mutation (HRRm) and/or homologous recombination deficiency (HRD): Initial results of the phase 2 KEYLYNK-007 study. Cancer Research 2021; 81: CT178
    CrossrefPubMedSearch in Google Scholar
  • 9 Rugo H, Robson M, Im SA. Pembrolizumab Plus Olaparib vs. Pembrolizumab Plus Chemotherpy After Induction With Pembrolizumab Plus Chemotherapy for Locally Recurrent Inoperable or Metastatic TNBC: Randomized, Open-Label, Phase 2 KEYLYNK-009 Study. San Antonio Breast Cancer Symposium (SABCS) 2023, San Antonio, 05 – 09th Decembre 2023. Presentation GS01-05.
    PubMed
  • 10 Azim H, El Saghir NS, Yap Y. et al. First-line ribociclib + endocrine therapy vs. combination chemotherapy in aggressive HR+/HER2- advanced breast cancer: a sub-group analysis of patients with or without vis-ceral crisis from the phase II RIGHT Choice study. Präsentation 402P. Accessed April 16, 2024 at: https://oncologypro.esmo.org/meeting-resources/esmo-congress-2023/first-line-ribociclib-rib-endocrine-therapy-et-vs-combination-chemotherapy-combo-ct-in-aggressive-hr-her2-advanced-breast-cancer-abc-a
  • 11 Wolff AC, Somerfield MR, Dowsett M. et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. Arch Pathol Lab Med 2023; 147: 993-1000
    CrossrefPubMedSearch in Google Scholar
  • 12 Sonke GS, van Ommen-Nijhof A, Wortelboer N. et al. Primary outcome analysis of the phase 3 SONIA trial (BOOG 2017-03) on selecting the optimal position of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors for patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC). J Clin Oncol 2023; 41: LBA1000
    CrossrefPubMedSearch in Google Scholar
  • 13 Decker T, Lüdtke-Heckenkamp K, Melnichuk L. et al. Anti-hormonal maintenance treatment with the CDK4/6 inhibitor ribociclib after 1st line chemotherapy in hormone receptor positive/HER2 negative metastatic breast cancer: A phase II trial (AMICA). Breast 2023; 72: 103575
    CrossrefPubMedSearch in Google Scholar
  • 14 Kalinsky K, Accordino MK, Chiuzan C. et al. Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: MAINTAIN Trial. J Clin Oncol 2023; 41: 4004-4013
    CrossrefPubMedSearch in Google Scholar
  • 15 Bidard F-C, Kaklamani VG, Neven P. et al. Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial. J Clin Oncol 2022; 40: 3246-3256
    CrossrefPubMedSearch in Google Scholar
  • 16 Bidard F-C, Kaklamani VG, Neven P. et al. Erratum: Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial. J Clin Oncol 2023; 41: 3962
    CrossrefPubMedSearch in Google Scholar
  • 17 Kaklamani V, Bidard FC, Neven P. et al. EMERALD phase 3 trial of elacestrant versus standard of care endocrine therapy in patients with ER+/HER2– metastatic breast cancer: Updated re-sults by duration of prior CDK4/6 inhibitor in metastatic setting. 2022 San Antonio Breast Cancer Symposium. Abstract GS3-01. Presented December 8, 2022.
    PubMed
  • 18 Turner NC, Oliveira M, Howell SJ. et al. Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med 2023; 388: 2058-2070
    CrossrefPubMedSearch in Google Scholar
  • 19 Rugo HS, Bardia A, Marmé F. et al. Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer. J Clin Oncol 2022; 40: 3365-3376
    CrossrefPubMedSearch in Google Scholar
  • 20 Rugo HS, Bardia A, Marmé F. et al. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial. Lancet 2023; 402: 1423-1433
    CrossrefPubMedSearch in Google Scholar
  • 21 Modi S, Jacot W, Yamashita T. et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med 2022; 387: 9-20
    CrossrefPubMedSearch in Google Scholar
  • 22 Bardia A, Hurvitz SA, Tolaney SM. et al. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. N Engl J Med 2021; 384: 1529-1541
    CrossrefPubMedSearch in Google Scholar
  • 23 Modi S, Andre F, Krop IE. et al. Trastuzumab deruxtecan for HER2-positive metastatic breast cancer: DESTINY-Breast01 subgroup analysis. J Clin Oncol 2020; 38: 1036
    CrossrefPubMedSearch in Google Scholar
  • 24 Hurvitz SA, Hegg R, Chung W-P. et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet 2023; 401: 105-117
    CrossrefPubMedSearch in Google Scholar
  • 25 André F, Hee Park Y, Kim S-B. et al. Trastuzumab deruxtecan versus treatment of physicianʼs choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial. Lancet 2023; 401: 1773-1785
    CrossrefPubMedSearch in Google Scholar
  • 26 Hurvitz S, Modi S, Li W. et al. A Pooled Analysis of Trastuzumab Deruxtecan in Patients With HER2-Positive Metastatic Breast Cancer With Brain Metastases from DESTINY-Breast01, -02 and -03. ESMO-Jahrestagung 2023, Madrid. Oral presentation #377PPS2023.
    PubMed
  • 27 Murthy RK, Loi S, Okines A. et al. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. N Engl J Med 2020; 382: 597-609
    CrossrefPubMedSearch in Google Scholar
  • 28 Chmura SJ, Winter KA, Woodward WA. et al. NRG-BR002: A phase IIR/III trial of standard of care systemic therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical resection (SR) for newly oligometastatic breast cancer (NCT02364557). J Clin Oncol 2022; 40: 1007
    CrossrefPubMedSearch in Google Scholar
  • 29 Dunst J. Kurative Strahlentherapie von Oligometastasen: Langzeitergebnisse der SABR-COMET-Studie. Strahlenther Onkol 2021; 197: 365-367
    CrossrefPubMedSearch in Google Scholar
  • 30 Cardoso F, Costa A, Senkus E. et al. 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC3). Ann Oncol 2017; 28: 16-33
    CrossrefPubMedSearch in Google Scholar
  • 31 Biganzoli L, Battisti NML, Wildiers H. et al. Updated recommendations regarding the management of older patients with breast cancer: a joint paper from the European Society of Breast Cancer Specialists (EUSOMA) and the International Society of Geriatric Oncology (SIOG). Lancet Oncol 2021; 22: e327-e340
    CrossrefPubMedSearch in Google Scholar
  • 32 Martinez-Tapia C, Paillaud E, Liuu E. et al. Prognostic value of the G8 and modified-G8 screening tools for multidimensional health problems in older patients with cancer. Eur J Cancer 2017; 83: 211-219
    CrossrefPubMedSearch in Google Scholar
  • 33 Decoster L, van Puyvelde K, Mohile S. et al. Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations†. Ann Oncol 2015; 26: 288-300
    CrossrefPubMedSearch in Google Scholar
  • 34 El Badri S, Tahir B, Balachandran K. et al. Palbociclib in combination with aromatase inhibitors in patients ≥ 75 years with oestrogen receptor-positive, human epidermal growth factor receptor 2 negative advanced breast cancer: A real-world multicentre UK study. Breast 2021; 60: 199-205
    CrossrefPubMedSearch in Google Scholar
  • 35 Carola E, Pulido M, Falandry C. et al. First-line systemic treatment with palbociclib in women aged ≥ 70 years presenting with hormone receptor-positive advanced breast cancer: Results from the PALOMAGE program. J Clin Oncol 2023; 41: 1018
    CrossrefPubMedSearch in Google Scholar
  • 36 Blum JL, Rocque G, Ji Y. et al. Impact of comorbidities on real-world patient-reported outcomes of patients with hormone receptor positive human epidermal growth factor 2 negative advanced breast cancer enrolled in the POLARIS trial. ESMO-Jahrestagung 2023, Madrid 20.–24.10.2023. #461P 2023.
    PubMed
  • 37 Tripathy D, Blum JL, Karuturi MS. et al. Impact of comorbidities on real-world clinical outcomes of patients with hormone receptor-positive/human epidermal growth factor 2-negative advanced breast cancer treated with palbociclib and enrolled in POLARIS. ESMO-Jahrestagung 2023; Madrid, 20.–24.10.2023. #373P.
    PubMed
  • 38 Roncato R, Angelini J, Pani A. et al. CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions. Int J Mol Sci 2020; 21
    CrossrefPubMedSearch in Google Scholar